Search - tctmd.com

Displaying 41 - 60 of 90

Sort: Relevancy | Date

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

Presentation TCT 2014

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

Presenter: Armando P?rez de Prado

September 16, 2014

Presentation TCT 2014

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Presenter: Jos? Mar?a Cubero G?mez

September 16, 2014

Presentation TCT 2014

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Presenter: Stefan K. James, Cindy L. Grines, Tracy Y. Wang

September 15, 2014

News Conference News TCT 2014

PLATO Subanalysis: Ticagrelor Safe, Effective in Primary PCI

September 15, 2014

News Conference News TCT 2014

Expert Discusses Potential Role for Platelet Function, Genetic Testing

September 15, 2014

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

News Conference News TCT 2014

Skeptic’s Corner: Experts Debate Aspirin Use in Patients with AF Receiving DES

Todd Neale

September 13, 2014

Presentation TCT 2013

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Presenter: Michelle O'Donoghue

October 31, 2013

Presentation TCT 2013

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

Presenter: E. Magnus Ohman

October 31, 2013

Presentation TCT 2013

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Presenter: Masato Nakamura

October 31, 2013

News Conference News TCT 2013

Studies Find Differing Benefits of Platelet, Genotype Testing

October 31, 2013

Presentation TCT 2013

Pre-load wtih Platelet ADP Receptor Inhibition in STEMI: Prasugrel, Ticagrelor, Clopidogrel, Or Does it Matter?

Presenter: Michel Le May

October 30, 2013

News Conference News TCT 2013

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

October 30, 2013

Advertisement

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

PLATO Subanalysis: Ticagrelor Safe, Effective in Primary PCI

Expert Discusses Potential Role for Platelet Function, Genetic Testing

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Skeptic’s Corner: Experts Debate Aspirin Use in Patients with AF Receiving DES

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Prasugrel Preloading in NSTEMI: ACCOAST Recap

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Studies Find Differing Benefits of Platelet, Genotype Testing

Pre-load wtih Platelet ADP Receptor Inhibition in STEMI: Prasugrel, Ticagrelor, Clopidogrel, Or Does it Matter?

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content